The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 350:1304-1313 March 25, 2004 Number 13
NextNext

Outcomes at School Age after Postnatal Dexamethasone Therapy for Lung Disease of Prematurity
Tsu F. Yeh, M.D., Yuh J. Lin, M.D., Hung C. Lin, M.D., Chao C. Huang, M.D., Wu S. Hsieh, M.D., Chyi H. Lin, M.D., and Cheng H. Tsai, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set

Commentary
-Editorial
 by Jobe, A. H.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
ABSTRACT

Background We studied the outcomes at school age in children who had participated in a double-blind, placebo-controlled trial of early postnatal dexamethasone therapy (initiated within 12 hours after birth) for the prevention of chronic lung disease of prematurity.

Methods Of the 262 children included in the initial study, 159 lived to school age. Of these children, 146 (72 in the dexamethasone group and 74 in the control group) were included in our study. All the infants had had severe respiratory distress syndrome requiring mechanical ventilation shortly after birth. In the dexamethasone group, 0.25 mg of dexamethasone per kilogram of body weight was given intravenously every 12 hours for one week, and then the dose was tapered. We evaluated the children's growth, neurologic and motor function, cognition, and school performance.

Results Children in the dexamethasone group were significantly shorter than the controls (P=0.03 for boys, P=0.01 for girls, and P=0.03 for all children) and had a significantly smaller head circumference (P=0.04). Children in the dexamethasone group had significantly poorer motor skills (P<0.001), motor coordination (P<0.001), and visual–motor integration (P=0.02). As compared with the controls, children in the dexamethasone group also had significantly lower full IQ scores (mean [±SD], 78.2±15.0 vs. 84.4±12.6; P=0.008), verbal IQ scores (84.1±13.2 vs. 88.4±11.8, P=0.04), and performance IQ scores (76.5±14.6 vs. 84.5±12.7, P=0.001). The frequency of clinically significant disabilities was higher among children in the dexamethasone group than among controls (28 of 72 [39 percent] vs. 16 of 74 [22 percent], P=0.04).

Conclusions Early postnatal dexamethasone therapy should not be recommended for the routine prevention or treatment of chronic lung disease, because it leads to substantial adverse effects on neuromotor and cognitive function at school age.


Source Information

From the Department of Pediatrics, China Medical University, Taichung (T.F.Y., H.C.L.); the National Chung-Kung University Hospital, Tainan (Y.J.L., C.C.H., C.H.L., C.H.T.); and the National Taiwan University Hospital, Taipei (W.S.H.) — all in Taiwan.

Address reprint requests to Dr. Yeh at the Department of Pediatrics, College of Medicine, China Medical Univeristy, 91 Hsueh-Shih Rd., Taichung 40421, Taiwan, or at master{at}mail.cmu.edu.tw.

Full Text of this Article


Related Letters:

Postnatal Dexamethasone for Lung Disease of Prematurity
Lommatzsch M., Klotz J., Virchow J. C. Jr., Watchko J. F., Brozanski B. S., Gordon P. V., Yeh T. F., Lin H. C., Huang C. C., Jobe A. H.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:2715-2718, Jun 24, 2004. Correspondence



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.